DiabetesHistaHeatNCT05921097
Comparison of Histamine and Local Heating for Evoking the Axon-reflex Flare Response in Diabetes
An observational study of Diabetes and Diabetes Mellitus, Type 1, run by Aalborg University Hospital at 1 site in Denmark.
Trial summary
Diabetic peripheral neuropathy is the most common complication to diabetes mellitus affecting as much as 50% of the population with diabetes. Symmetrical sensory neuropathy is by far the most common pattern, which often progress slowly over many years, although some individuals experience faster and more severe… Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Diabetes, Diabetes Mellitus, Type 1, Diabetic Neuropathy Peripheral
- What is being tested?
- Histamin-induced axon-reflex flare response, Local heating-induced axon-reflex flare response and 2-point discrimination tasks
- How many people
- 40 participants
- Where
- 1 siteDenmark
- Study dates
- 17 Jun 2023to 29 Jul 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- Adult, Older adult
Study population: People with T1DM
Who may be able to join
- Age 18-75 years and diagnosed with type 1 diabetes
Who cannot join
- Known critical limb ischemia (ankle-brachial index < 50 mmHg or toe-brachial index < 30 mmHg)
- Symptoms of claudicatio intermittens
- Inability to do without antihistamine for 24h prior to examination
- Known neurological disease (e.g., multiple sclerosis)
- Severe skin diseases on either foot (e.g., fulminant pemphigoid)
- Previous or current alcohol or drug abuse
Show all 13Show fewer
- Previous or current chemotherapy or current disseminated cancer
- Known cause of neuropathy other than diabetes
- Previous amputation on either foot
- Active diabetic foot ulcer on either foot
- Pregnancy
- Inability to participate or other condition thought to impact the results (evaluated by investigator)
- Asymmetrical neuropathy (i.e., previous accident with radiating pain)
Trial locations and contacts
1 site in 1 country.
About this study
Diabetic peripheral neuropathy is the most common complication to diabetes mellitus affecting as much as 50% of the population with diabetes. Symmetrical sensory neuropathy is by far the most common pattern, which often progress slowly over many years, although some individuals experience faster and more severe courses. Despite the frequent occurrence, the causes of diabetic peripheral neuropathy are largely unknown, which is reflected in the fact that no disease-modifying treatments are available for preventing, treating or even halting the progression of the disease. The consequences can be dire, as neuropathy frequently leads to foot ulcers, amputations or intolerable neuropathic pain in the lower extremities. Sensory loss may go completely undetected in diabetes, as there often are literally no symptoms. For many individuals, the development of diabetic peripheral neuropathy can therefore proceed completely unnoticed, making regular screening the most important tool for diagnosing the condition. Unfortunately, unlike nephropathy or retinopathy, diabetic peripheral neuropathy is not easily screened for, as the condition lacks reliable markers for early- or progressing disease. Therefore, screening for diabetic peripheral neuropathy currently revolves around diagnosing loss of protective sensation, judged by the inability to feel vibration or light touch. However, in their most recent guidelines, the American Diabetes Association has included screening for small fibre neuropathy using either the cold- and heat perception thresholds or pinprick as a clinical standard. Although this acknowledgement of the importance of assessing not only large- but also small nerve fibres is a huge step towards early detection of diabetic peripheral neuropathy, the overriding issue of insensitive, unreproducible, and inaccurate bedside tests for small nerve fibres remains. While cold- and heat perception and pinprick sensation are indeed mediated by small nerve fibres, the sensitivity of these methods, outside of extreme standardization only achievable in dedicated neuropathy research-centres, remain poor and not usable on an individual level. This lack of sensitivity has also become apparent in several large clinical trials, where the methods have continuously failed as robust clinical endpoints. Due to this, the hunt for a sensitive and reproducible method for adequate assessment of the small nerve fibres have begun. Amongst several interesting methods, two have gained particular interest (corneal confocal microscopy and skin biopsies with quantification of intra-epidermal nerve fiber density), due to their diverse strengths, although clinical application is currently limited to a few specialized sites. Furthermore, both methods suffer several inherent issues including that fact that they only provide information about the structure of the nerves and not the function. One method to assess the function of small cutaneous C-fibers is the assessment of the axon reflex flare response using laser doppler imaging (LDI) or Full-field laser perfusion imaging (FLPI), which has classically been studied using local heating. Unfortunately, this method is limited in clinical usage due to time-consumption. The investigators recently published an alternative method using a simple skin-prick application of histamine to evoke the response, which reduced the examination-time markedly. Before claiming the method to be a better alternative, the investigators do however need to prove that the method is as good as the original.
In addition to the direct comparison of the histamine-induced and the heating-induced axon-reflex flare response the study will also assess spatial acuity in the same cohort as a secondary aim. Spatial acuity is considered as a measure of the sensory systems ability to code spatial information regarding an external stimulus. To investigate the spatial acuity, the 2-point discrimination task (2PDT) is often used. Spatial acuity has been shown to be impaired in several chronic pain condition. Additionally, it has been shown that the 2PDT may be a useful tool to understand the sensory changes in diabetes[8].
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetic Neuropathy Peripheral, Small Fiber Neuropathy
- Being tested
- Histamin-induced axon-reflex flare response, Local heating-induced axon-reflex flare response, 2-point discrimination tasks, NC-Stat DPNCheck, QST
- Keywords
- Diabetes, Neuropahty
- Medical subject headings
- Diabetes Mellitus, Diabetes Mellitus, Type 1, Small Fiber Neuropathy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Histamin-induced axon-reflex flare responseDiagnostic test
Histamin-induced axon-reflex flare response
Local heating-induced axon-reflex flare responseDiagnostic test
Local heating-induced axon-reflex flare response
2-point discrimination tasksDiagnostic test
2-point discrimination tasks
NC-Stat DPNCheckDiagnostic test
NC-Stat DPNCheck
QSTDiagnostic test
Also called Quantitative Sensory Testing, thermal
QST
BiothesiometryDiagnostic test
Also called VPT
Biothesiometry
| Study group | Role | What they receive |
|---|---|---|
| T1DM | People with type 1 diabetes Receives: Diagnostic Test: Histamin-induced axon-reflex flare response; Diagnostic Test: Local heating-induced axon-reflex flare response; Diagnostic Test: 2-point discrimination tasks; Diagnostic Test: NC-Stat DPNCheck; Diagnostic Test: QST; Diagnostic Test: Biothesiometry |
What is being measured
The primary outcome is the main question the study is designed to answer.
Comparison of histamine and local heating (area size)
The evoked area (assessed by full-field laser speckle perfusion imaging) by histamine and local heating will be compared as a proxy for small fiber neuropathy in diabetes
Measured: Through study completion, an average of 1-2 years
Comparison of axon-reflex flare responses with QST
Comparison of axon reflex flare responses with an established method (area size vs cold and heat detection threshold)
Measured: Through study completion, an average of 1-2 years
Secondary outcomes (2)
2PDT in diabetes with and without DPN
Assess spatial acuity through 2PDT in people with diabetes with and without DPN.
Measured: Through study completion, an average of 1-2 years
Comparison of axon-reflex flare responses with NC-Stat DPNCheck
Comparison of axon reflex flare responses with an established method (sural nerve conduction velocity/amplitude)
Measured: Through study completion, an average of 1-2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Jun 2023
- Study start17 Jun 2023
- Primary completion17 Jun 2024
- Study completion29 Jul 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for DiabetesStudies of the same condition, open and under way.
- More trials run by Aalborg University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 40 participants (actual)
Sponsor and investigators
- Lead sponsor
- Aalborg University Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- Aalborg University
- Responsible party
- Principal investigator, Johan Bovbjerg Røikjer, Aalborg University Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05921097
- Sponsor's protocol ID
- N-20230007
- Acronym
- HistaHeat
- Status last verified
- Jul 2024
- First submitted
- 7 Jun 2023
- Last updated
- 30 Jul 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Jul 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Histamine and Local Heating for Evoking the Axon-reflex Flare Response in Diabetes
- ClinicalTrials.gov ID
- NCT05921097
- Acronym / sponsor ID
- HistaHeat / N-20230007
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetic Neuropathy Peripheral, Small Fiber Neuropathy
- Keywords
- Diabetes, Neuropahty
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 40 participants (actual)
- Lead sponsor
- Aalborg University HospitalUniversity, hospital or other
- Collaborators
- Aalborg University
- Study start
- 17 Jun 2023 (actual)
- Primary completion
- 17 Jun 2024 (actual)
- Study completion
- 29 Jul 2024 (actual)
- First posted
- 27 Jun 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Diabetic peripheral neuropathy is the most common complication to diabetes mellitus affecting as much as 50% of the population with diabetes. Symmetrical sensory neuropathy is by far the most common pattern, which often progress slowly over many years, although some individuals experience faster and more severe courses. Despite the frequent occurrence, the causes of diabetic peripheral neuropathy are largely unknown, which is reflected in the fact that no disease-modifying treatments are available for preventing, treating or even halting the progression of the disease. The consequences can be dire, as neuropathy frequently leads to foot ulcers, amputations or intolerable neuropathic pain in the lower extremities. Sensory loss may go completely undetected in diabetes, as there often are literally no symptoms. For many individuals, the development of diabetic peripheral neuropathy can therefore proceed completely unnoticed, making regular screening the most important tool for diagnosing the condition. Unfortunately, unlike nephropathy or retinopathy, diabetic peripheral neuropathy is not easily screened for, as the condition lacks reliable markers for early- or progressing disease. Therefore, screening for diabetic peripheral neuropathy currently revolves around diagnosing loss of protective sensation, judged by the inability to feel vibration or light touch. However, in their most recent guidelines, the American Diabetes Association has included screening for small fibre neuropathy using either the cold- and heat perception thresholds or pinprick as a clinical standard. Although this acknowledgement of the importance of assessing not only large- but also small nerve fibres is a huge step towards early detection of diabetic peripheral neuropathy, the overriding issue of insensitive, unreproducible, and inaccurate bedside tests for small nerve fibres remains. While cold- and heat perception and pinprick sensation are indeed mediated by small nerve fibres, the sensitivity of these methods, outside of extreme standardization only achievable in dedicated neuropathy research-centres, remain poor and not usable on an individual level. This lack of sensitivity has also become apparent in several large clinical trials, where the methods have continuously failed as robust clinical endpoints. Due to this, the hunt for a sensitive and reproducible method for adequate assessment of the small nerve fibres have begun. Amongst several interesting methods, two have gained particular interest (corneal confocal microscopy and skin biopsies with quantification of intra-epidermal nerve fiber density), due to their diverse strengths, although clinical application is currently limited to a few specialized sites. Furthermore, both methods suffer several inherent issues including that fact that they only provide information about the structure of the nerves and not the function. One method to assess the function of small cutaneous C-fibers is the assessment of the axon reflex flare response using laser doppler imaging (LDI) or Full-field laser perfusion imaging (FLPI), which has classically been studied using local heating. Unfortunately, this method is limited in clinical usage due to time-consumption. The investigators recently published an alternative method using a simple skin-prick application of histamine to evoke the response, which reduced the examination-time markedly. Before claiming the method to be a better alternative, the investigators do however need to prove that the method is as good as the original.
In addition to the direct comparison of the histamine-induced and the heating-induced axon-reflex flare response the study will also assess spatial acuity in the same cohort as a secondary aim. Spatial acuity is considered as a measure of the sensory systems ability to code spatial information regarding an external stimulus. To investigate the spatial acuity, the 2-point discrimination task (2PDT) is often used. Spatial acuity has been shown to be impaired in several chronic pain condition. Additionally, it has been shown that the 2PDT may be a useful tool to understand the sensory changes in diabetes[8].
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| T1DM | – | Diagnostic Test: Histamin-induced axon-reflex flare response, Diagnostic Test: Local heating-induced axon-reflex flare response, Diagnostic Test: 2-point discrimination tasks, Diagnostic Test: NC-Stat DPNCheck, Diagnostic Test: QST, Diagnostic Test: BiothesiometryPeople with type 1 diabetes |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- People with T1DM
Key inclusion criteria (1 listed)
- Age 18-75 years and diagnosed with type 1 diabetes
Key exclusion criteria (13 listed)
- Known critical limb ischemia (ankle-brachial index < 50 mmHg or toe-brachial index < 30 mmHg)
- Symptoms of claudicatio intermittens
- Inability to do without antihistamine for 24h prior to examination
- Known neurological disease (e.g., multiple sclerosis)
- Severe skin diseases on either foot (e.g., fulminant pemphigoid)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Histamin-induced axon-reflex flare responseHistamin-induced axon-reflex flare response | Diagnostic test | T1DM |
| Local heating-induced axon-reflex flare responseLocal heating-induced axon-reflex flare response | Diagnostic test | T1DM |
| 2-point discrimination tasks2-point discrimination tasks | Diagnostic test | T1DM |
| NC-Stat DPNCheckNC-Stat DPNCheck | Diagnostic test | T1DM |
| QSTAlso: Quantitative Sensory Testing, thermalQST | Diagnostic test | T1DM |
| BiothesiometryAlso: VPTBiothesiometry | Diagnostic test | T1DM |
Primary outcome
Comparison of histamine and local heating (area size)
Time frame: Through study completion, an average of 1-2 years
The evoked area (assessed by full-field laser speckle perfusion imaging) by histamine and local heating will be compared as a proxy for small fiber neuropathy in diabetes
Comparison of axon-reflex flare responses with QST
Time frame: Through study completion, an average of 1-2 years
Comparison of axon reflex flare responses with an established method (area size vs cold and heat detection threshold)
2 secondary outcomes
2PDT in diabetes with and without DPN
Time frame: Through study completion, an average of 1-2 years
Comparison of axon-reflex flare responses with NC-Stat DPNCheck
Time frame: Through study completion, an average of 1-2 years
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Jul 2024.
- Individual participant dataSharing planned: No
Related trials for Diabetes
Not yet recruitingPhase 3
Efficacy and Safety of Once-Weekly SHR-3167 Compared With Once-Daily Insulin Glargine in Adults With Insulin-Naive Type 2 Diabetes
Type 2 Diabetes
Active, not recruiting
Digital Reinforcement of Motivational Interviewing Micro-Skills Among Primary Care Healthcare Professionals
Hypertension (Without Type 2 Diabetes Mellitus)
Recruiting
Effects of Lean Pork Loin Intake on Protein Homeostasis and Glucose Regulation in Prediabetic Adults
Hyperglycaemia (Non Diabetic), Prediabetes
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Recruiting
Investigating Vascular Properties of HEMI and SPG Signals in Individuals With or at Risk for Chronic Kidney Disease
Chronic Kidney Disease, Hypertension (HTN)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Diabetes and Diabetes Mellitus, Type 1, run by Aalborg University Hospital at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Comparison of histamine and local heating (area size) (time frame: Through study completion, an average of 1-2 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Jul 2024.